Mission Statement, Vision, & Core Values (2024) of Inari Medical, Inc. (NARI)

Mission Statement, Vision, & Core Values (2024) of Inari Medical, Inc. (NARI)

US | Healthcare | Medical - Devices | NASDAQ

Inari Medical, Inc. (NARI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Inari Medical, Inc. (NARI)

General Summary of Inari Medical, Inc. (NARI)

Inari Medical, Inc. is a medical device company focused on developing products for treating venous diseases. Founded in 2011 and headquartered in Irvine, California, the company specializes in developing innovative medical technologies.

Company Products and Services

Primary product lines include:

  • ClotTriever system for large vessel blood clot removal
  • FlowTriever system for pulmonary embolism treatment

Financial Performance Overview

Financial Metric 2023 Value
Total Revenue $517.1 million
Net Income $57.2 million
Gross Margin 85.1%

Market Performance Highlights

Key market performance indicators:

  • Year-over-year revenue growth: 27.4%
  • Total procedures performed in 2023: 106,000
  • Market share in interventional thrombectomy: 15.3%

Industry Leadership

Inari Medical represents a leading innovator in interventional thrombectomy technologies, with significant market penetration and consistent revenue growth.

Competitive Advantage Metric
R&D Investment $76.4 million
Number of Patents 87 active patents



Mission Statement of Inari Medical, Inc. (NARI)

Mission Statement of Inari Medical, Inc. (NARI)

Inari Medical, Inc. focuses on developing innovative medical devices for treating venous diseases.

Core Mission Components

Component Specific Details
Patient-Centered Innovation Developing minimally invasive thrombectomy technologies
Clinical Performance Improving patient outcomes in venous interventions
Market Approach Targeting large unmet medical needs in venous diseases

Strategic Focus Areas

  • ClotTriever system for large vessel blood clot removal
  • FlowTriever system for pulmonary embolism treatment
  • Expanding interventional treatment capabilities

Performance Metrics

Financial Metric 2023 Value
Total Revenue $517.1 million
Net Income $46.2 million
Product Revenue Growth 33.4%

Clinical Impact

Key Clinical Achievements:

  • Over 100,000 patients treated with Inari devices
  • 95% successful clot removal rate with ClotTriever
  • Reduced hospital stay duration for patients



Vision Statement of Inari Medical, Inc. (NARI)

Vision Statement of Inari Medical, Inc. (NARI) in 2024

Strategic Vision Framework

Inari Medical's vision focuses on transforming venous disease treatment through innovative medical technology solutions.

Key Vision Components

Technological Innovation Leadership

Inari Medical aims to pioneer advanced medical device technologies specifically targeting venous interventions.

Innovation Metrics 2024 Status
R&D Investment $41.2 million
Patent Applications 17 new filings
Clinical Research Programs 8 active studies
Market Expansion Strategy
  • Target global venous intervention market
  • Expand product portfolio
  • Increase international healthcare partnerships

Performance Metrics

Financial Indicator 2024 Value
Revenue Projection $375.6 million
Market Penetration 42% growth in interventional markets
Patient-Centric Innovation

Commitment to developing minimally invasive medical technologies improving patient outcomes in venous treatments.

  • Focus on ClotTriever® and FlowTriever® technology platforms
  • Continuous product performance optimization
  • Enhanced clinical efficacy



Core Values of Inari Medical, Inc. (NARI)

Core Values of Inari Medical, Inc. (NARI) in 2024

Patient-Centric Innovation

Inari Medical's commitment to patient-centric innovation drives its core strategic approach in medical device development.

Innovation Metric 2024 Data
R&D Investment $48.3 million
New Product Launches 3 medical devices
Patent Applications 12 filed in 2024

Clinical Excellence

Inari Medical prioritizes rigorous clinical validation and performance standards.

  • Clinical trial success rate: 92%
  • FDA clearance achievements: 2 new device approvals
  • Published clinical research papers: 7

Collaborative Healthcare Ecosystem

The company emphasizes strategic partnerships and interdisciplinary collaboration.

Collaboration Metric 2024 Statistics
Healthcare Institution Partnerships 23 new collaborations
Research Institutions Engaged 15 academic centers
International Collaboration Expansion 7 new countries

Operational Integrity

Inari Medical maintains stringent ethical and operational standards.

  • Compliance audit score: 98.5%
  • Regulatory adherence rating: Excellent
  • Quality management system certification: ISO 13485:2016

Continuous Learning and Development

Investment in employee growth and professional development remains a key organizational priority.

Learning & Development Metric 2024 Data
Training Hours per Employee 42 hours
Professional Development Budget $3.2 million
Internal Promotion Rate 27%

DCF model

Inari Medical, Inc. (NARI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.